A new subgroup analysis across the MONALEESA phase III program found that patients with visceral metastases who were treated with Kisqali (ribociclib) plus endocrine therapy in the first-line setting achieved a median OS of 62.7 months compared to 52.1 months for those treated with endocrine therapy alone.
Breast cancer treatment has changed dramatically over the past decade. One of the most important advances has been our growing ability to understand the biology of each patient’s cancer and use those insights to guide treatment decisions more precisely. That shift is helping make personalized cancer care a reality.
